ArticleCancers2022

HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study.

Francesca Carlino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.